Washington, D.C. — A renewed effort is underway in the United States to reduce the cost of prescription medications, as federal officials prepare to revisit a proposal that would align certain drug prices with the lower rates found in other developed countries.
According to individuals familiar with the matter, the proposal—known as a “most favored nation” pricing policy—could be advanced through an executive order in the coming days. The initiative would apply to a selection of drugs covered under Medicare and aims to bring U.S. prices closer to those paid by other nations, where prescription medications often cost significantly less.
The plan, still under internal review, is being shaped by senior administration officials and healthcare policy advisers. If finalized, it would represent a major shift in how the federal government negotiates—or benchmarks—the cost of medications purchased for millions of Americans.
Renewed Focus on Healthcare Costs
While no official details have been confirmed, sources say the announcement could come early next week. In recent meetings, the President has hinted at an upcoming announcement related to healthcare, calling it “very big” and “one of the most important” in recent years.
This policy approach is not new. A similar version was first introduced several years ago but faced legal and regulatory obstacles that stalled its implementation. At the time, the plan encountered resistance from both pharmaceutical companies and legal experts who questioned the method of enforcement.
Despite past hurdles, the rising cost of prescription drugs continues to be a pressing concern for many Americans, particularly older adults and individuals with chronic conditions. By tying U.S. prices to those charged in other countries, advocates of the proposal hope to create a more balanced and fair pricing system.
Industry Response and Legal Outlook
The pharmaceutical industry is expected to push back against the plan, with some companies arguing that the pricing model could limit resources for innovation and research. Legal experts have also noted that similar efforts in the past faced challenges in court due to procedural issues.
Still, administration officials appear committed to exploring ways to reduce medication costs without waiting for new legislation from Congress. Previous attempts to include a similar provision in broader health legislation did not gain enough support in the legislative process.
What Comes Next
If the executive order is signed, it would likely trigger a period of review and public comment before being implemented. Details on which medications might be included, how prices will be determined, and the timeline for rollout have not yet been made public.
Health policy analysts say that while the proposal could face significant resistance, it reflects growing momentum toward rethinking how prescription drugs are priced in the U.S. compared to other countries.
For now, Americans watching this development hope that any future changes will lead to more affordable and accessible medication options, particularly for seniors and those reliant on Medicare.
